Simplify Logo

Full-Time

Regional Sales Manager

Eastern North America

Posted on 6/18/2024

Ultima Genomics

Ultima Genomics

201-500 employees

High-throughput genomic sequencing services

Hardware
Biotechnology

Compensation Overview

$110k - $160kAnnually

Senior, Expert

Remote in USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Communications
Requirements
  • B.S in Biology or related discipline
  • Working knowledge of genomics technology, NGS, and its application in research, clinical, and other applied markets
  • Minimum 8 years in Life Science and/or Clinical diagnostics sales/sales management
  • Ability to travel 50% of the time and be located within 1-2 hours of major airport
  • Demonstrated experience of being the earliest or first commercial lead in a large territory or region for a start-up or new business endeavor
  • Adept at operating with a high degree of independence and self-motivation
  • Skilled at seeking out and engaging with key opinion leaders, CEOs, CSOs, Heads of Assay Development
  • Experienced with selling new technologies and capabilities from the earliest days of inception, while competing against large, established incumbents
  • Results- and accountability-oriented mentality
  • Demonstrated experience working in team/matrixed environments
  • Strong understanding of life science research and clinical genomics market segments
  • Well-developed network and ability to successfully influence/lead decision making across teams and functional groups
  • Strong business and strategic acumen
  • Strong communication skills
Responsibilities
  • Leads development of territory sales strategy and plans
  • Ensures territory is set up to deliver quarterly and annual revenue consistent with assigned sales quota
  • Develops and maintains relationships with key customers in the region
  • Directly drive account relationships and sales to achieve Ultima’s sales goals
  • Foster connectedness of field-based team
  • Set the tone, build the culture as one of the first

Ultima Genomics improves human health through advanced genomic sequencing technologies, processing large amounts of genetic data to provide insights into biology and diseases. Its unique sequencing architecture allows for extensive data collection, detection of small genetic variations, and routine testing for early disease detection. This capability gives clients, including researchers and healthcare providers, access to high-quality genomic information. The company's goal is to continuously innovate and expand its services to enable significant advancements in understanding and treating diseases.

Company Stage

Seed

Total Funding

$631.8M

Headquarters

Newark, New Jersey

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Ultima Genomics' partnerships with organizations like Hartwig Medical Foundation and Genome Insight enhance their capabilities in precision oncology and cancer diagnostics.
  • The commercial launch of the UG 100 system positions Ultima Genomics as a leader in the high-throughput genomics market, potentially driving significant revenue growth.
  • Their continuous innovation and advancements in sequencing technology could lead to groundbreaking discoveries and improvements in human health.

What critics are saying

  • The high cost of developing and maintaining advanced sequencing technologies could strain Ultima Genomics' financial resources.
  • The competitive landscape in the genomics industry is intense, with numerous players vying for market share, which could impact Ultima's growth.

What makes Ultima Genomics unique

  • Ultima Genomics' UG 100 system and ppmSeq technology offer significantly lower sequencing costs and ultra-high accuracy, setting them apart from traditional sequencing technologies.
  • Their focus on making whole genome sequencing affordable and accessible for cancer diagnostics is a unique value proposition in the genomics market.
  • The company's innovative sequencing architecture, featuring an open silicon wafer substrate, enables the $100 genome, a groundbreaking achievement in the industry.
INACTIVE